Assertio Holdings Completes Merger with Zydus Lifesciences
Assertio Holdings finalizes its acquisition by Zydus Lifesciences, triggering key provisions for holders of its 2027 convertible notes.
Assertio Holdings, Inc., the Lake Forest, Illinois-based specialty pharmaceutical company traded on Nasdaq under the ticker ASRT, has completed its merger with India's Zydus Lifesciences Ltd., marking a significant ownership transition for the publicly listed drugmaker. The deal was executed under a merger agreement originally signed on May 13, 2026, with Zydus Worldwide DMCC — a Zydus entity incorporated in the United Arab Emirates — serving as an intermediary vehicle in the transaction structure.
The closing of the merger carries immediate and material consequences for Assertio's debt holders. Under the terms governing the company's outstanding 6.50% Convertible Senior Notes due 2027, the completion of the transaction constitutes what bond indentures define as a "Fundamental Change" — a contractual trigger that typically grants noteholders the right to require the company to repurchase their securities at par, or in some cases at a premium. The merger also qualifies as a "Make-Whole Fundamental Change," a related provision designed to compensate convertible noteholders for lost optionality by temporarily increasing the conversion rate under prescribed conditions.
Read more Eli Lilly Expands Pain Pipeline With 4E Therapeutics Acquisition →
For investors still holding Assertio's convertible notes, the dual designation is consequential. A standard Fundamental Change puts a repurchase option in noteholders' hands, while the Make-Whole component is intended to ensure that any conversion executed during the defined window doesn't leave debt investors worse off than if they had held equity outright. Together, these provisions represent the bondholder-protection architecture that convertible note issuers are required to honor when control of a company changes hands.
The Zydus Lifesciences acquisition fits a broader pattern of Indian generic pharmaceutical companies expanding their U.S. commercial footprints through direct acquisitions rather than organic growth — a strategy accelerated by the relatively compressed valuations of mid-cap U.S. specialty pharma names in recent years. Assertio, which focused on commercializing non-opioid pain and neurological drugs, offered Zydus an established U.S. sales infrastructure alongside branded product assets.
Continue reading at BusinessWire.
